Gossamer Bio reported a significant revenue beat for the third quarter of 2026, primarily driven by $25.1 million in one-time revenue recognized following the termination of its collaboration with Chiesi Farmaceutici. While the company submitted its first New Drug Application (NDA) for seralutinib in September, its net loss per share was wider than analyst expectations due to non-cash financial charges.
Key Highlights
- Revenue surged to $38.4 million, largely reflecting the accounting impact of reacquiring worldwide rights to seralutinib.
- Net loss was $48.1 million, or $7.36 per share, missing the estimated loss of $5.55; results were impacted by a $56.5 million non-cash charge for warrant liability remeasurement.
- Research and development expenses decreased 59% year-over-year to $18.8 million as Phase 3 clinical costs for seralutinib tapered off.